Federated Hermes Inc. Purchases Shares of 1,749,650 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Federated Hermes Inc. acquired a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,749,650 shares of the company’s stock, valued at approximately $42,429,000. Federated Hermes Inc. owned approximately 1.31% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CNTA. Campbell & CO Investment Adviser LLC bought a new stake in Centessa Pharmaceuticals during the second quarter worth about $218,000. American Century Companies Inc. raised its stake in shares of Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after acquiring an additional 37,954 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Centessa Pharmaceuticals by 27.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock worth $7,355,000 after acquiring an additional 121,611 shares in the last quarter. Bollard Group LLC bought a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $1,319,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $725,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at $3,159,078. The trade was a 24.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $24.89 on Friday. The company has a market cap of $3.35 billion, a PE ratio of -13.60 and a beta of 1.56. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company’s 50-day moving average is $25.63 and its two-hundred day moving average is $22.30.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on CNTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial lifted their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim increased their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Stephens started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.